Celcuity (NASDAQ:CELC) Given Buy Rating at HC Wainwright

Celcuity (NASDAQ:CELC - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $27.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 212.14% from the stock's previous close. HC Wainwright also issued estimates for Celcuity's Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at $1.50 EPS and FY2029 earnings at $3.63 EPS.

Separately, Needham & Company LLC lifted their price objective on Celcuity from $23.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $30.17.

Celcuity Trading Down 2.3 %

CELC stock traded down $0.20 during mid-day trading on Tuesday, hitting $8.65. 502,142 shares of the company were exchanged, compared to its average volume of 294,085. Celcuity has a 12-month low of $7.70 and a 12-month high of $20.15. The firm has a market capitalization of $321.17 million, a P/E ratio of -3.31 and a beta of 0.44. The business has a fifty day simple moving average of $10.99 and a 200-day simple moving average of $12.77. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.13). On average, equities research analysts predict that Celcuity will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its stake in shares of Celcuity by 21.6% in the fourth quarter. Wellington Management Group LLP now owns 62,776 shares of the company's stock valued at $822,000 after acquiring an additional 11,165 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Celcuity by 19.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,377 shares of the company's stock valued at $345,000 after purchasing an additional 4,341 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in shares of Celcuity by 106.0% in the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company's stock valued at $33,577,000 after buying an additional 1,319,700 shares during the period. Shay Capital LLC acquired a new position in shares of Celcuity during the fourth quarter worth about $187,000. Finally, Nuveen Asset Management LLC increased its stake in shares of Celcuity by 10.8% during the fourth quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company's stock worth $911,000 after buying an additional 6,785 shares during the period. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.